Supernus Pharmaceuticals (SUPN -3.14%) recently announced that it's acquiring Adamas Pharmaceuticals (ADMS). In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acquisition of Adamas is a smart move.
10 stocks we like better than Supernus Pharmaceuticals
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Supernus Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 17, 2021
Keith Speights: Let's switch gears a little bit here, Brian, and talk about some recent biotech acquisitions.
On Monday, Supernus Pharmaceuticals, the ticker there is SUPN, announced that it's buying Adamas Pharmaceuticals, ticker there is ADMS. What do you think of the deal, Brian? Is this a smart move or not-so-smart move for Supernus?
Brian Orelli: I think it's a smart move for Supernus. It's a good fit. It diversifies the company away from Trokendi which is approved for migraine and makes up a bulk of its sales. It gets two marketed drugs from Adamas -- Gocovri and Osmolex, which are both for Parkinson's disease. Supernus already sells two other drugs for Parkinson's disease so there's potential for quite a bit of synergies here.
The company estimates that it could be $60 million to $80 million in year one, so that's a substantial savings. Then the deal has an interesting structure. They are paying $8.10 upfront in cash per share.
But then there's a contingent value to CRV for $1 that's tied to the sales of Gocovri. It's $0.50 if the sales reach two different levels by 2024 and 2025. That seems like a long time to wait just for an additional dollar per share, although obviously, it could come a lot earlier than 2024 or 2025. It doesn't really seem to be factored into the share price at close.
When I looked yesterday, it was trading just under $8.10. Basically, the investors had basically discounted that potential for that extra dollar, or at least it's not worth it to bid up above the $8.10 mark.
Speights: That is a really interesting deal structure as you mentioned. But it's always encouraging to see deals like this that do appear to be good fits that the products that the two companies bring together could make the whole be greater than the sum of the parts. We'll see how this works out.
